腹主动脉瘤破裂腔内修复术后腹腔间隔室综合征:单中心全腔内治疗经验
本研究回顾性分析瑞典厄勒布鲁大学医院2009年10月至2021年9月连续100例仅接受EVAR治疗的破裂腹主动脉瘤患者,17例发生腹腔间隔室综合征(ACS)。ACS组30天死亡率为53%(9/17),无ACS组为22%(18/83,p=0.015);回归分析显示ACS使死亡风险增加4倍(HR 4.26,CI 1.99-9.10,p<0.001),年龄每增加1岁风险增加6%(HR 1.06,CI 1.06-1.1,p=0.004)。作者结论认为所有EVAR治疗的rAAA患者应密切监测ACS,并及时行减压开腹术。
要点
- 100例EVAR治疗的rAAA患者中17例发生ACS,ACS组30天死亡率53% vs 无ACS组22%(p=0.015)。
- ACS为死亡独立危险因素(HR 4.26,CI 1.99-9.10,p<0.001),年龄每岁增加风险6%(HR 1.06,CI 1.06-1.1,p=0.004)。
- 主动脉球囊阻断与ACS发生无独立关联;作者建议所有EVAR治疗的rAAA患者密切监测ACS并及时减压开腹。
核心结论
- ACS是EVAR治疗rAAA后危及生命的并发症,相当数量患者发生ACS且死亡率和并发症率高。
- 作者认为所有EVAR治疗的rAAA患者应密切监测ACS,并及时启动减压开腹术治疗。
研究设计与样本
- 回顾性分析前瞻性收集的数据,纳入2009年10月至2021年9月在厄勒布鲁大学医院因rAAA就诊的139例患者。
- 排除孤立髂动脉、胸主动脉及胸腹主动脉破裂、既往主动脉干预(开放或腔内)及接受姑息治疗的患者。
- 最终100例接受EVAR治疗的患者纳入分析,发生ACS的17例与未发生ACS的83例进行比较。
主要发现
- ACS组30天死亡率为53%(9/17),无ACS组为22%(18/83),p=0.015。
- 回归分析显示高龄和ACS是死亡的独立危险因素,ACS使死亡风险增加4倍(HR 4.26,CI 1.99-9.10,p<0.001)。
- 年龄每增加1岁死亡风险增加6%(HR 1.06,CI 1.06-1.1,p=0.004)。
- 主动脉球囊阻断的使用与ACS发生无独立关联。
关键数值与推荐
- ACS组30天死亡率53%(9/17) vs 无ACS组22%(18/83),p=0.015。
- ACS对死亡的HR 4.26(CI 1.99-9.10,p<0.001);年龄对死亡的HR 1.06(CI 1.06-1.1,p=0.004)。
临床怎么用
- 作者认为所有EVAR治疗的rAAA患者应密切监测ACS。
- 作者认为一旦发生ACS应及时启动减压开腹术治疗,不应延迟。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Open repair of ruptured abdominal aortic aneurysms (rAAA) has been increasingly replaced by endovascular aortic repair (EVAR) in many centers. Despite being a minimally invasive procedure, EVAR is associated with a risk of abdominal compartment syndrome (ACS), which can lead to significant morbidity and mortality. This study examines the incidence and clinical manifestation of ACS in a consecutive cohort of rAAA patients treated exclusively with EVAR at Örebro University Hospital over a 12-year period. METHODS: This is a retrospective analysis of prospectively collected data. We identified 139 patients who had presented to Örebro University Hospital with rAAA between October 2009 and September 2021. Patients with isolated iliac artery, thoracic and thoracoabdominal aortic ruptures, previous aortic interventions (open or endovascular), and patients receiving palliative treatment were excluded. Patients developing ACS after rAAA were compared with those who did not develop ACS. RESULTS: A total of 100 patients treated using EVAR were included in this study. ACS was identified in 17 patients, and these were compared with 83 patients who did not develop ACS. Mortality at 30 days was 53% in the ACS group (9/17) and 22% in the No-ACS group (18/83, p = 0.015). Regression analysis showed that advanced age and ACS were independent risk factors for death, with ACS increasing the hazard 4-fold (HR 4.26, CI 1.99-9.10, p < 0.001) and age increasing the hazard by 6% for every year (HR 1.06, CI 1.06-1.1, p = 0.004). The use of aortic balloon occlusion was not independently associated with the development of ACS. CONCLUSIONS: ACS is a life-threatening complication of rAAA treated using EVAR and a significant number of patients developed ACS with high mortality and complication rates. All rAAA patients treated using EVAR should be monitored closely for ACS and treatment with decompressive laparotomy should be initiated without delay.Clinical ImpactOpen repair of ruptured abdominal aortic aneurysms (rAAA) has been increasingly replaced by endovascular aortic repair (EVAR). Despite being a minimally invasive procedure, EVAR is associated with a risk of abdominal compartment syndrome (ACS), which can lead to significant morbidity and mortality This article investigates abdominal compartment syndrome (ACS) in a cohort of total endovascular treated rAAA in a single centre and the treatment as well as the results, and gives insight on ACS in this patient group and might contribute to better understanding how to treat them and avoid this life-threatening complication.
引用
- Hörer TM, Abu-Zidan FM, McGreevy DT, et al. Abdominal Compartment Syndrome After Endovascular Repair of Ruptured Abdominal Aortic Aneurysms: A Single-Center Experience of Total Endovascular Care for Ruptured Abdominal Aneurysms. J Endovasc Ther. 2025. PMID: 40165640. doi:10.1177/15266028251328494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。